

## **SUPPLEMENTARY INFORMATION**

### **Cbr1 is a Dph3 reductase required for the tRNA wobble uridine modification**


Zhewang Lin, Min Dong, Yugang Zhang, Eunyoung Alisa Lee, Hening Lin\*

Howard Hughes Medical Institute, Department of Chemistry and Chemical Biology, Cornell University, Ithaca, New York, 14853.


\* Corresponding author

## SUPPLEMENTARY RESULTS


- Supplementary Figure 1** Reaction schemes for diphthamide and tRNA wobble uridine modifications.
- Supplementary Figure 2** Dph3 interactome study identifies Cbr1 as a potential Dph3 reductase.
- Supplementary Figure 3** Cbr1 uses NADH but not NADPH for Dph3 reduction.
- Supplementary Figure 4** *CBR1* or *MCR1* deletion strains are not resistant to DT.
- Supplementary Figure 5** Reduction of Dph3 by Mcr1, Pga3 and Ncp1.
- Supplementary Figure 6** Time course for treatment of isolated tRNAs with  $\gamma$ -toxin.
- Supplementary Figure 7** Full gel images for Figure 1c.
- Supplementary Figure 8** Full gel images for Supplementary Figure 5d.
- Supplementary Figure 9** Full gel images for Figure 2d.
- Supplementary Table 1** List of strains used.
- Supplementary Table 2** List of primers used.




**Supplementary Figure 1.** Reaction schemes for diphthamide and tRNA wobble uridine modification. (A) Diphthamide biosynthesis pathway in eukaryotes. (B) tRNA wobble uridine modifications in eukaryotes.




**Supplementary Figure 2.** Dph3 interactome study identifies Cbr1 as a potential Dph3 reductase. (A) Schematic workflow of the Dph3 SILAC interactome study. (B) A list of proteins with high H/L ratios from Dph3 SILAC interactome study. 500 was set as the maximum H/L ratio to make it mathematically meaningful for peptides not detected in the light sample. The table lists protein with H/L ratio greater than 10.




**Supplementary Figure 3.** Cbr1 uses NADH but not NADPH for Dph3 reduction. Reduction of Dph3 by Cbr1 was monitored using the 488 nm absorbance of oxidized Dph3. Figure is representative of three experimental repeats.



**Supplementary Figure 4.** DT sensitivity assay showing that diphthamide formation is not affected in Cbr1 or Mcr1 deletion strains. The strains used are specified on the left. Each row represents a serial dilution from left to the right. Figure is representative of three biological triplicates.




**Supplementary Figure 5.** Mcr1 and Ncp1 reduce Dph3 *in vitro*. (A) Reduction of Dph3 by Mcr1 monitored using the 488 nm absorbance of oxidized Dph3. (B) Reduction of Dph3 by Pga3 monitored using the 488 nm absorbance of oxidized Dph3. (C) Reduction of Dph3 by Ncp1 monitored using the 488 nm absorbance of oxidized Dph3. (D) *In vitro* reconstitution of the first step of diphthamide biosynthesis on eEF2 using Dph1-2, carboxy-<sup>14</sup>C-SAM in the presence of either Mcr1/NADH or Ncp1/NADPH. Autoradiography shows labeled eEF2 substrate. Bottom panel shows eEF2 stained with Coomassie blue. Supplementary Figure 5a, 5b and 5c are representative of three experimental repeats. Supplementary Figure 5d shows representative image from two experimental repeats. Full gel images for Supplementary Figure 5d are shown in Supplementary Figure 9.



**Supplementary Figure 6.** Time course for *In vitro*  $\gamma$ -toxin treatment of isolated tRNA from cells. Samples were analyzed by northern blot with glu-tRNA 5' probe. The positions of the full length or cleaved glu-tRNA are labeled on the left. Figure shows representative image from two experimental repeats.





|            |   |   |   |   |   |
|------------|---|---|---|---|---|
| Dithionite | + | - | - | - | - |
| Dph3       | - | - | + | + | + |
| Cbr1       | - | - | + | + | - |
| NADH       | - | - | + | - | + |
|            | 1 | 2 | 3 | 4 | 5 |




**Supplementary Figure 7.** Full gel images for Figure 1c.

|       |   |   |   |   |   |   |
|-------|---|---|---|---|---|---|
| Mcr1  | - | - | + | + | - | - |
| Ncp1  | - | - | - | - | + | + |
| NADH  | + | - | + | - | - | - |
| NADPH | - | + | - | - | + | - |
|       | 1 | 2 | 3 | 4 | 5 | 6 |



**Supplementary Figure 8.** Full gel images for Supplementary Figure 5d.



**Supplementary Figure 9.** Full gel images for Figure 2d.

**Supplementary Table1. Yeast strains used**

| Strain  | Genotype  | Source                              |
|---------|---|-------------------------------------|
| HL813Y  | <i>MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0</i>  | Open Biosystems (YSC1048)           |
| HL1352Y | <i>MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 dph3-6xGLY-3xFLAG::HIS3MX6</i>                 | This study                          |
| HL815Y  | <i>MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 dph2Δ::KANMX</i>                               | Open Biosystems (YSC1021-553846)    |
| HL1429Y | <i>MATa his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 dph3Δ::KANMX</i>                                | Open Biosystems (YSC6273-201938235) |
| HL1355Y | <i>MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 cbr1Δ::KANMX</i>                               | Open Biosystems (YSC6273-201920517) |
| HL1396Y | <i>MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 mcr1Δ::KANMX</i>                               | Open Biosystems (YSC6273-201936518) |
| HL1439Y | <i>MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 cbr1Δ::KANMX mcr1Δ::NATMX6</i>                 | This study                          |
| HL1400Y | <i>MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 cbr1Δ::KANMX mcr1Δ::NATMX6 aim33Δ::HIS3MX6</i> | This study                          |
| HL1433Y | <i>MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 elp3Δ::KANMX</i>                               | Open Biosystems (YSC6273-201929585) |
| HL1401Y | HL813Y [pLF16, <i>CEN LEU2</i> UASGAL-γ-toxin]                                      | This study                          |
| HL1402Y | HL815Y [pLF16, <i>CEN LEU2</i> UASGAL-γ-toxin]                                      | This study                          |
| HL1403Y | HL1429Y [pLF16, <i>CEN LEU2</i> UASGAL-γ-toxin]                                     | This study                          |
| HL1405Y | HL1355Y [pLF16, <i>CEN LEU2</i> UASGAL-γ-toxin]                                     | This study                          |
| HL1406Y | HL1396Y [pLF16, <i>CEN LEU2</i> UASGAL-γ-toxin]                                     | This study                          |
| HL1407Y | HL1439Y [pLF16, <i>CEN LEU2</i> UASGAL-γ-toxin]                                     | This study                          |
| HL1442Y | HL1433Y [pLF16, <i>CEN LEU2</i> UASGAL-γ-toxin]                                     | This study                          |
| HL1416Y | HL813Y [pHL1025, p416 GALS DT-F2 (N45D)]  | This study                          |
| HL1417Y | HL815Y [pHL1025, p416 GALS DT-F2 (N45D)]  | This study                          |
| HL1418Y | HL1429Y [pHL1025, p416 GALS DT-F2 (N45D)]   | This study                          |

**Supplementary Table1. Continued**

| Strain  | Genotype   | Source     |
|---------|--|------------|
| HL1419Y | HL1355Y [pHL1025, p416 GALS DT-F2 (N45D)] <sup>a</sup>                       | This study |
| HL1420Y | HL1396Y [pHL1025, p416 GALS DT-F2 (N45D)]                                    | This study |
| HL1440Y | HL1439Y [pHL1025, p416 GALS DT-F2 (N45D)]                                    | This study |
| HL1441Y | HL1400Y [pHL1025, p416 GALS DT-F2 (N45D)]                                    | This study |
| HL1443Y | HL813Y [pHL610E, p423 met25 eEF2 C-His] <sup>b</sup>                         | This Study |
| HL1444Y | HL1429Y [pHL610E, p423 met25 eEF2 C-His]                                     | This Study |
| HL1445Y | HL1355Y [pHL610E, p423 met25 eEF2 C-His]                                     | This Study |
| HL1446Y | HL1396Y [pHL610E, p423 met25 eEF2 C-His]                                     | This Study |
| HL1447Y | HL1439Y [pHL610E, p423 met25 eEF2 C-His]                                     | This Study |
| HL1448Y | HL813Y [pHL610E, p423 met25 eEF2 C-His;<br>pHL1025, p416 GALS DT-F2 (N45D)]  | This Study |
| HL1449Y | HL1429Y [pHL610E, p423 met25 eEF2 C-His;<br>pHL1025, p416 GALS DT-F2 (N45D)] | This Study |
| HL1450Y | HL1355Y [pHL610E, p423 met25 eEF2 C-His;<br>pHL1025, p416 GALS DT-F2 (N45D)] | This Study |
| HL1451Y | HL1396Y [pHL610E, p423 met25 eEF2 C-His;<br>pHL1025, p416 GALS DT-F2 (N45D)] | This Study |
| HL1452Y | HL1439Y [pHL610E, p423 met25 eEF2 C-His;<br>pHL1025, p416 GALS DT-F2 (N45D)] | This Study |

<sup>a</sup> Source reference for p416 GALS DT-F2 (N45D): Su, X. et al. *Proc Natl Acad Sci USA* 109, 19983-19987 (2012).

<sup>b</sup> Source reference for p423 met25 eEF2 C-His: Su, X. et al. *J Am Chem Soc.* 134, 773–776 (2012).

## Supplementary Table 2. List of primers used

### Primers for constructing endogenous Dph3 FLAG tag

ZL210 GCAGGCATCCACCCCCCTGAGCCTATTGCCGCTGCTGCCcggatccccgggtaattaa

ZL211 CTTTATTTCTATTTGTATTCTCGATCTAGCCTCTCATCTgaattcgagctcgtttaaac

### Primers for deletion of *mcr1* gene

ZL244 ATAACGTATATAGGTTAAAATAATATTCCAAGTCAAAAACcggatccccgggtaattaa

ZL245 ATCCGAAATTAATAAATAATCAATTACTTTCTCCATGCgaattcgagctcgtttaaac

### Primers for verification of *mcr1* deletion

ZL354 ATAACGTATATAGGTTAAAATAATATTCC

ZL307 CAATTACTTTCCTCCATGC

### Primers for deletion of *aim33* gene

ZL242 TATCACATTTTTTCTTTGTAAAAGCAACCATTGCAACAcggatccccgggtaattaa

ZL243 TGCTTATTTACATGAAAATCATCAATCGTAAACAGTTGAgaattcgagctcgtttaaac

### Primers for verification of *aim33* deletion

ZL250 GTATGTTTAGTATTAACATATCAC

ZL251 AAATACGAATATATATCTAAATATAATTAATGC

### Primers for the *cbr1* gene

ZL224 CAGAGTGAATTCAAGACCAAGCCTGTGCT

ZL222 AGTCAGCTCGAGTTAAAACACAAACACCTGGT

### Primers for the *pga3* gene

ZL234 AGTCAGGGATCCAAAAGAAGAAGATCACTGTA

ZL235 AGTCAGCTCGAGTTAAAAGACGAAGACTTGAT

**Primers for the *mcr1* gene**

ZL240 CAGAGTGAATTCAACCGTAACCAACATTCC

ZL241 AGTCAGCTCGAGTTAAAATTTGAAAACCTTGGT

**Primers for the *ncp1* gene**

ZL316 AGTCAGCCATGGGCCATCATCATCATCATATGTCCGATGACGGAGATAT

ZL318 AGTCAGCTCGAGTTACCAGACATCTTCTTGGTAT

**Primers for the  $\gamma$ -toxin**

ZL436 AGTCAGCCATGGGCCATCATCATCATCATCATCATGCAGCTACTACTGCGAGA

ZL437 AGTCAGCTCGAGTTATACACATTTTCCATTCTGTAG